5.32
-0.04 (-0.75%)
| Penutupan Terdahulu | 5.36 |
| Buka | 5.41 |
| Jumlah Dagangan | 2,113,926 |
| Purata Dagangan (3B) | 3,571,357 |
| Modal Pasaran | 3,250,125,824 |
| Harga / Jualan (P/S) | 26.22 |
| Harga / Buku (P/B) | 2.84 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 21 Aug 2025 - 25 Aug 2025 |
| Margin Operasi (TTM) | -549.59% |
| EPS Cair (TTM) | -0.560 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -15.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 29.32% |
| Nisbah Semasa (MRQ) | 6.53 |
| Aliran Tunai Operasi (OCF TTM) | -321.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -310.27 M |
| Pulangan Atas Aset (ROA TTM) | -15.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ANTENGENE-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ANTENGENE-B | 3 B | - | - | 2.84 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
|
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 35.63% |
| % Dimiliki oleh Institusi | 24.97% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |